[视力恢复的基因治疗]。

Kazuhiko Namekata, Xiaoli Guo, Chikako Harada, Takayuki Harada
{"title":"[视力恢复的基因治疗]。","authors":"Kazuhiko Namekata, Xiaoli Guo, Chikako Harada, Takayuki Harada","doi":"10.1254/fpj.24053","DOIUrl":null,"url":null,"abstract":"<p><p>Glaucoma is an age-related neurodegenerative disease and the leading cause of blindness, but currently no fundamental treatment has been present. The main treatment is to reduce intraocular pressure, which is expected to delay the progression of the disease. However, there are many glaucoma patients for whom progression cannot be controlled by lowering intraocular pressure alone, and the development of a fundamental treatment is required. Meanwhile, the clinical application of gene therapy is increasing worldwide. Various gene therapy vectors are still being developed, and technological change is much faster in this field. Gene therapy has already been clinically applied to several neurodegenerative diseases, but gene therapy for glaucoma has not yet been established. Our group is investigating the development of a new treatment for glaucoma by gene therapy using neurotrophic factor signaling. And we aim not only to suppress disease progression by neuroprotection, but also to recover the visual function by axonal regeneration.</p>","PeriodicalId":12208,"journal":{"name":"Folia Pharmacologica Japonica","volume":"160 1","pages":"19-22"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Gene therapy for visual function recovery].\",\"authors\":\"Kazuhiko Namekata, Xiaoli Guo, Chikako Harada, Takayuki Harada\",\"doi\":\"10.1254/fpj.24053\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Glaucoma is an age-related neurodegenerative disease and the leading cause of blindness, but currently no fundamental treatment has been present. The main treatment is to reduce intraocular pressure, which is expected to delay the progression of the disease. However, there are many glaucoma patients for whom progression cannot be controlled by lowering intraocular pressure alone, and the development of a fundamental treatment is required. Meanwhile, the clinical application of gene therapy is increasing worldwide. Various gene therapy vectors are still being developed, and technological change is much faster in this field. Gene therapy has already been clinically applied to several neurodegenerative diseases, but gene therapy for glaucoma has not yet been established. Our group is investigating the development of a new treatment for glaucoma by gene therapy using neurotrophic factor signaling. And we aim not only to suppress disease progression by neuroprotection, but also to recover the visual function by axonal regeneration.</p>\",\"PeriodicalId\":12208,\"journal\":{\"name\":\"Folia Pharmacologica Japonica\",\"volume\":\"160 1\",\"pages\":\"19-22\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Folia Pharmacologica Japonica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1254/fpj.24053\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Folia Pharmacologica Japonica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1254/fpj.24053","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

青光眼是一种与年龄相关的神经退行性疾病,也是致盲的主要原因,但目前还没有根本的治疗方法。主要的治疗方法是降低眼压,这有望延缓疾病的进展。然而,有许多青光眼患者的进展不能通过单独降低眼压来控制,需要开发一种基础治疗方法。同时,基因治疗在世界范围内的临床应用也在不断增加。各种基因治疗载体仍在开发中,该领域的技术变革要快得多。基因治疗已在临床上应用于几种神经退行性疾病,但对青光眼的基因治疗尚未建立。我们小组正在研究利用神经营养因子信号的基因疗法治疗青光眼的新方法。我们的目标不仅是通过神经保护来抑制疾病的进展,而且是通过轴突再生来恢复视觉功能。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Gene therapy for visual function recovery].

Glaucoma is an age-related neurodegenerative disease and the leading cause of blindness, but currently no fundamental treatment has been present. The main treatment is to reduce intraocular pressure, which is expected to delay the progression of the disease. However, there are many glaucoma patients for whom progression cannot be controlled by lowering intraocular pressure alone, and the development of a fundamental treatment is required. Meanwhile, the clinical application of gene therapy is increasing worldwide. Various gene therapy vectors are still being developed, and technological change is much faster in this field. Gene therapy has already been clinically applied to several neurodegenerative diseases, but gene therapy for glaucoma has not yet been established. Our group is investigating the development of a new treatment for glaucoma by gene therapy using neurotrophic factor signaling. And we aim not only to suppress disease progression by neuroprotection, but also to recover the visual function by axonal regeneration.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Folia Pharmacologica Japonica
Folia Pharmacologica Japonica Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
0.40
自引率
0.00%
发文量
132
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信